We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novavax Vaccine Shown to Be 96 Percent Effective Against Original SAR-Cov-2 Virus
Novavax Vaccine Shown to Be 96 Percent Effective Against Original SAR-Cov-2 Virus
Novavax said its COVID-19 vaccine demonstrated 96.4 percent efficacy against mild, moderate and severe forms of the original SARS-CoV-2 strain in the final analysis from its phase 3 UK trial.